Nanoscope Therapeutics Expands into AMD with Phase 2 Trial as Long-Term RP Data Matures — Nanoscope Therapeutics Inc.

Event summary

Nanoscope to present first direct-to-Phase 2 trial data for optogenetic therapy in geographic atrophy (AMD) at ASRS meeting on July 16.
3-year follow-up data from RESTORE Phase 2b/3 trial of MCO-010 in retinitis pigmentosa to be unveiled.
Company plans to initiate Phase 3 trial for Stargardt disease and Phase 2 program for geographic atrophy in 2026.

The big picture

Nanoscope's expansion into age-related macular degeneration represents a strategic pivot toward larger patient populations after establishing proof-of-concept in retinitis pigmentosa. The company's disease-agnostic platform positions it uniquely in the optogenetic therapy space, though success will depend on demonstrating consistent efficacy across diverse retinal conditions. With multiple regulatory designations already secured and Phase 3 trials planned for Stargardt disease, Nanoscope is positioning itself as a potential leader in vision restoration therapies.

What we're watching

Therapeutic Expansion: Whether Nanoscope can successfully translate its optogenetic approach from RP to AMD, a significantly larger market opportunity.
Regulatory Momentum: The pace at which the FDA processes Nanoscope's BLA submission for MCO-010 in retinitis pigmentosa following positive Phase 2b/3 results.
Clinical Validation: How durable vision improvements from MCO-010 prove to be across multiple retinal degenerative diseases based on emerging long-term data.